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Raised serum levels of interferon (IFN)-
 
 
 
 have been observed in systemic lupus erythematosus 
(SLE) patients, and these levels are correlated with both disease activity and severity. The 
origin of this IFN-
 
 
 
 is still unclear, but increasing evidence suggests the critical involvement 
of activated plasmacytoid predendritic cells (PDCs). In SLE patients, DNA and RNA viruses, 
as well as immune complexes (ICs), that consist of autoantibodies specific to self-DNA and 
RNA protein particles can stimulate production of IFN-
 
 
 
. We have developed three series of 
oligonucleotide (ODN)-based inhibitors of Toll-like receptor (TLR) signaling. These ODNs 
include inhibitors of TLR9, inhibitors of TLR7 but not TLR9, and sequences that inhibit both 
TLR7 and TLR9. Specificity of these inhibitors is confirmed by inhibition of IFN-
 
 
 
 production 
by PDCs in response to DNA or RNA viruses. We show that mammalian DNA and RNA, in the 
form of ICs, are potent self-antigens for TLR9 and TLR7, respectively, and induce IFN-
 
 
 
 
production by PDCs. This work suggests that TLRs may have a critical role in the promotion 
of lupus through the induction of IFN-
 
 
 
 by PDCs. These inhibitors of TLR signaling thus 
represent novel therapeutic agents with potential for the treatment of lupus.
 
After the discovery of the protein Toll as a sig-
naling receptor for immunity in 
 
Drosophila me-
lanogaster
 
, several homologous Toll-like receptors
(TLRs) have been identified in mammals.
TLRs are key receptors of the innate immune
system and recognize a diverse range of con-
served microbial molecules (1, 2). 4 out of the
10 TLRs identified in humans recognize nucleic
acids, demonstrating the fundamental importance
of microbial DNA and RNA in triggering innate
responses to pathogenic microorganisms (3–6).
TLR-mediated activation can initiate rapid and
effective control of infection; however, the con-
sequences to the host can be chronic or acute
inflammation. Microbial sepsis is the best known
example of this, and the roles of TLR2 and
TLR4 in sepsis have been clearly demonstrated
(7). TLR3 has recently been shown to be re-
quired for the central nervous system inflamma-
tion leading to the disruption of the blood–brain
barrier during West Nile virus infection in mice
(8). This demonstrates that the nucleic acid
component of a pathogen, in this example an
RNA virus, can trigger inflammation destructive
to host tissues. In addition, TLR activation by
endogenous ligands has been reported in some
types of sterile inflammation as well (9, 10).
TLR2 and TLR4 are described to respond to
endogenous heat-shock proteins, TLR4 to ex-
tracellular matrix fragments, fibrinogen and
 
 
 
-defensin (11, 12), and TLR3 to mRNA (13),
all of which may be present at elevated levels at
sites of tissue injury and inflammation. Similarly,
DNA–anti-DNA IgG immune complexes (ICs)
have been shown to stimulate autoantibody
production in mice by a process involving
TLR9 (14). By analogy to the adaptive immune
system, the innate immune system appears to
require mechanisms for self–nonself discrimina-
tion, and failure of these mechanisms may con-
tribute to inflammation and autoimmunity. Dis-
crimination between nucleic acids of mammalian
versus microbial origin by TLRs is particularly
difficult, and the expression of the DNA- and
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RNA-specific TLRs in endosomal vesicles, but not on the
cell surface (2), may represent one mechanism for restricting
the response to nucleic acids from invading microorganisms.
Increased serum levels of IFN-
 
 
 
 and elevated expression
of a characteristic set of IFN-
 
 
 
–inducible genes in blood
cells has been consistently observed in systemic lupus erythe-
matosus (SLE) patients and has been shown to be correlated
with disease activity (15–18). These elevated IFN-
 
 
 
 levels
may have a direct role in the pathology of lupus, because pa-
tients with nonautoimmune disorders who are treated with
IFN-
 
 
 
 can develop antinuclear antibodies, anti–double-
stranded (ds) DNA antibodies, and occasionally lupus (19).
The source of the elevated IFN-
 
 
 
 in SLE may be plasmacy-
toid pre-DCs (PDCs) (20), the major IFN-
 
 
 
–producing cell
type in blood. These cells appear to be chronically activated
in SLE patients where a 100-fold decrease in the number of
PDCs circulating in the blood has been observed (20, 21).
This decrease appears caused by in vivo activation followed
by cell migration into peripheral lymphoid tissues and sites of
inflammation such as cutaneous lesions (22, 23).
This activation of PDCs could result from signals recog-
nized by TLRs, because the most efficient known inducers of
IFN-
 
 
 
 by PDCs are synthetic ligands for TLR7 and TLR9
and DNA and RNA viruses, most likely acting through these
same TLRs (5, 24). Furthermore, viral infections have been
linked to disease exacerbations in SLE patients (18). A second
possible signal for IFN-
 
 
 
 induction in SLE is triggering by ICs
of autoantibodies containing self-DNA or RNA (19, 25, 26).
Clearance of apoptotic cells by macrophages is deficient in SLE
patients and may promote the formation of these ICs resulting
from autoantibodies reactive with autoantigens that contain
nucleic acid (RNA and DNA). Fc
 
 
 
RII is expressed on PDCs
and can internalize ICs, targeting the ICs to endosomal com-
partments that contain TLR7 and TLR9 (27–29). Ronnblom
and Alm have demonstrated the ability of both types of com-
plexes to stimulate IFN-
 
 
 
 production from PBMCs in vitro,
although the involvement of TLR was not tested (19). The
nucleic acids are key components of the anti-dsDNA and anti-
ribonucleoprotein (anti-RNP) ICs because treatment with nu-
cleases completely abolished their ability to induce IFN-
 
 
 
 in
this system (25), and ICs from serum not containing anti-
dsDNA or anti-RNP antibodies do not induce IFN-
 
 
 
 (29).
Therefore, inhibiting the signaling through TLR7 and TLR9
could control this activation pathway that leads to IFN-
 
 
 
 pro-
duction and should result in strong benefit for lupus patients.
We and others have described several distinct subsets of
atypical, nonstimulatory DNA sequences that can inhibit
TLR9 stimulation by CpG-containing immunostimulatory
sequences (ISS) (30–36). These sequences have been identi-
fied from diverse sources, including viral sequences, mutated
CpG sequences, or repeats of the TTAGGG motif present in
mammalian telomeres (30–38). Most of these studies have
been confined to mouse models, but we have recently
shown that such TLR9 inhibitors were also active on human
cells and, importantly, could inhibit IFN-
 
 
 
 production from
PDCs in response to CpG-ISS (36). We have termed these
inhibitors immunoregulatory DNA sequences (IRS), as they
act to regulate immunostimulatory TLR9 ligands (36). No
DNA or RNA sequences have yet been reported to inhibit
TLR7-mediated activation.
We describe novel classes of oligonucleotide (ODN)-
based inhibitors of TLRs, including inhibitors of both TLR7
and TLR9 signaling. We show that these IRS can inhibit
IFN-
 
 
 
 production from human PDCs in response to both
DNA and RNA viruses as well as to stimulation by ICs iso-
lated form lupus patients.
 
RESULTS
Identification of inhibitors specific for mouse TLR7 
and TLR9 signaling
 
Our prototype for TLR9 inhibitors is IRS 869 (36). This se-
quence efficiently inhibits TLR9 activation by ISS but has no
Figure 1. Identification of inhibitors specific for mouse TLR7 and 
TLR9 signaling. Splenocytes from BALB/c mice were stimulated for 48 h 
with (A) 0.7  M 1018 ISS or (B) 1  M R848 alone or in the presence of IRS 
869 (open squares), IRS 661 (open circles), or IRS 954 (closed triangles) at 
different concentrations. IL-6 production was measured by ELISA and 
plotted as a percentage of 1018 ISS (A) or R848 alone (B). Maximum levels 
of IL-6 varied between 1,663 and 4,266 pg/ml for 1018 ISS and between 
924 and 2,721 pg/ml for R848. Values represent the means   SEM of four 
independent experiments. 
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effect when splenocytes are activated with the TLR7 ligand
R848 (Fig. 1, A and B). We now describe two new classes of
IRS: inhibitors of TLR7 but not TLR9 and inhibitors of
stimulation through these two receptors (Fig. 1 and Table I).
One type of inhibitor, represented by IRS 661, specifically
reduced responses of mouse splenocytes to the TLR7 agonist
R848, but not to a CpG-ISS that signal through TLR9
ligands (Fig. 1, A and B). The second new type of inhibitors,
exemplified by IRS 954, was derived by combining sequence
elements from both IRS 661 and IRS 869 (Table I) and pro-
vides considerable inhibition of splenocyte activation by both
TLR7 and TLR9 ligands (Fig. 1). As shown in Table I, IRS
967 comprises the TLR7 inhibitor IRS 661 and the TLR9
inhibitor IRS 869 and inhibits signaling through either TLR.
IRS 957 and IRS 954 show that the ODN can be shortened
such that only the three 5
 
 
 
 residues from IRS 661 are needed
to confer complete TLR7 inhibitory activity on an ODN
with TLR9 inhibitory activity only. Further reduction or al-
teration of this motif results in progressive loss of the ability to
inhibit TLR7 (IRS 986, 987, and 988). Given that many po-
tent agonists for TLR7 are molecules the size of a single nu-
cleotide, such as R848, and many are adenosine or guanosine
analogues, perhaps it is not surprising that a motif of a few
nucleotides might confer an antagonist activity. Substantially
more IRS was necessary to block the response to R848 ver-
sus 1018 ISS, which may reflect the relative affinities of ago-
nist and antagonist for these two receptors. However, cellular
uptake of R848, a small molecule, and larger ODNs may be
quite different, and external concentrations of each may not
reflect the relative concentrations in the endosome. Interest-
ingly, the inhibition by IRS 954 did not extend to other
TLR ligands because there was little to no inhibition of
CD11c
 
 
 
 splenocytes activated by Pam3Cys, Poly I:C, LPS,
or Flagellin, which use TLR2, -3, -4, and -5, respectively
(Fig. 2). We have shown that IRS could inhibit TLR9 acti-
vation in vivo (36). We then asked whether IRS 954 could
also block TLR7 activation. Mice were injected with the
TLR7 ligand R848, and IL-12 levels in the serum were mea-
sured 2 h after the injection. When mice were preinjected
with IRS 954 with varying amounts, a substantial reduction
in IL-12 response was observed, whereas the inactive control
ODN did not inhibit (Fig. 3).
Figure 2. IRS do not affect signaling through other TLRs. Purified 
CD11c-positive splenocytes from BALB/c mice were stimulated for 48 h 
with either 5  g/ml LPS, 0.1  g/ml Pam3Cys, 1  g/ml Flagellin, or 50  g/ml 
Poly I:C alone or in the presence of IRS 954 at different concentrations. 
IL-6 production was measured by ELISA and plotted as a percentage of the 
stimuli alone. Means of maximum levels were 1,620 pg/ml (LPS), 2,463 pg/ml 
(Pam3Cys), 880 pg/ml (Flagellin), and 678 pg/ml (Poly I:C). Values represent 
means   SEM of five independent experiments.
 
Table I.
 
TLR7 and TLR9 inhibition is associated with specific sequence motifs
 
0.7 
 
 
 
M 1018 ISS 1 
 
 
 
M R848
ODN concentration ODN concentration
 
1.4 
 
 
 
M 0.35 
 
 
 
M 0.08 
 
 
 
M 5.6 
 
 
 
M 1.4 
 
 
 
M 0.35 
 
 
 
M
 
Alone 100 100 100 100 100 100
IRS 869: 5
 
 
 
-TCCTGGAGGGGTTGT-3
 
 
 
7 12 32 93 110 104
IRS 661: 5
 
 
 
-TGCTTGCAAGCTTGCAAGCA-3
 
 
 
78 81 84 21 47 77
IRS 967: 5
 
 
 
-TGCTTGACAGCTTGACAGCATCCTGGAGGGGTTGT-3
 
 
 
128 1 6 4 9 8 0
IRS 957: 5
 
 
 
-TGCTTGACATCCTGGAGGGGTTGT-3
 
 
 
2 4 10 17 39 78
IRS 954: 5
 
 
 
-TGCTCCTGGAGGGGTTGT-3
 
 
 
4 7 19 23 44 72
IRS 986: 5
 
 
 
-GCTCCTGGAGGGGTTGT-3
 
 
 
1 2 33 38 85 128
IRS 987: 5
 
 
 
-CTCCTGGAGGGGTTGT-3
 
 
 
1 1 11 107 128 142
IRS 988: 5
 
 
 
-AAATCCTGGAGGGGTTGT-3
 
 
 
3 32 84 66 95 117
Ctrl-ODN: 5
 
 
 
-TCCTGCAGGTTAAGT-3
 
 
 
104 102 97 108 108 105
 
Splenocytes from BALB/c mice were stimulated for 48 h with 0.7 
 
 
 
M 1018 ISS or 1 
 
 
 
M R848 alone or in the presence of different IRS sequences at variable concentrations as 
indicated. Underlined motifs are responsible for TLR7 inhibition. IL-6 production was measured by ELISA and plotted as a percentage of 1018 ISS or R848 alone. Means of four 
independent experiments are shown. 
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IRS retain function and specificity in human cells
 
We next investigated whether these IRS had similar activity
and specificity in humans by examining their ability to
block human B cell activation. As observed in the mouse
system, IRS 869 inhibits TLR9 but not TLR7, IRS 661 in-
hibits TLR7 but not TLR9, and IRS 954 inhibits responses
to ligands for either receptor (Fig. 4). TLR8 is also a func-
tional receptor for R848 and RNA in humans, but not in
mice (2). Although PDCs and B cells express little TLR8,
other cell types in the blood do express TLR8 and can be
activated by SLE serum. In particular, human monocytes,
have little TLR7 but express high levels of TLR8 (Fig.
S1 A, available at http://www.jem.org/cgi/content/full/
jem.20050914/DC1). The TLR7 inhibitor IRS 661 has lit-
tle to no effect on activation of highly purified monocytes
by R848 (Fig. S1 B), suggesting that TLR8 responses are
not inhibited by such IRS. We cannot rule out, however,
that IRS are inactive in monocytes for reasons unrelated to
receptor specificity.
 
IRS specific for TLR7 act independently of TLR9
 
The ability of short DNA sequences to inhibit signaling
through TLR7, a receptor specific for single-stranded RNA,
was unexpected. One possible explanation is that IRS is rec-
ognized by TLR9, and this leads to blockade of signaling
through components shared by TLR7 and TLR9, such as
MyD88 or IFN regulatory factor–7 (2, 39). We tested
whether TLR9 was involved in the inhibition by IRS of
TLR7 stimulation by testing IRS activity on cells from
TLR9-deficient mice (3). Splenocytes from WT or TLR9-
deficient mice were stimulated with R848 alone or in the
presence of the TLR7 inhibitors IRS 661 or IRS 954. Both
types of IRS decreased R848-induced IL-6 equally well in
WT and TLR9-deficient mice (Fig. 5 A), excluding a role
for TLR9 in the inhibition of TLR7-mediated responses.
The response to 1018 ISS was inhibited by IRS 954, but not
IRS 661, in WT mice and was absent in TLR9 deficient
mice (Fig. 5 B).
 
IRS inhibit IFN-
 
 
 
 from human PDCs after stimulation with 
DNA or RNA viruses
 
We have shown recently that IRS can inhibit IFN-
 
 
 
 produc-
tion from human PDCs in response to CpG-containing ISS
(36). This latter activity is of particular importance to lupus,
as IFN-
 
 
 
 produced by PDCs in response to virus or ICs may
play an important role in the pathogenesis of this disease. To
test the ability of IRS to inhibit IFN-
 
 
 
 induction by more
complex but more physiologically relevant stimuli, purified
PDCs were stimulated with either UV-irradiated HSV (a
DNA virus) or inactivated influenza virus (a single-stranded
RNA virus, also known as flu), both of which are strong
IFN-
 
 
 
 inducers in PDCs. Levels of IFN-
 
 
 
 production
ranged between 5 and 95 ng/ml (mean 
 
  
 
25.6 ng/ml) in re-
sponse to HSV and between 3.5 and 63 ng/ml (mean 
 
 
 
 30.8
ng/ml) in response to flu. IRS 954, but not IRS 661, inhib-
ited IFN-
 
 
 
 production in a dose-dependent manner from
PDCs stimulated with HSV (Fig. 6, A and B), whereas both
IRS 661 and IRS 954 could significantly inhibit IFN-
 
 
 
 pro-
duction in response to flu (P 
 
 
 
 0.001; Fig. 6, C and D).
PDCs represent only a small proportion of the total blood
cells; however, similar findings were obtained using total PB-
MCs (unpublished data). These results demonstrate that
DNA and RNA viruses can induce IFN-
 
 
 
 by human PDCs
through the stimulation of TLR9 and TLR7, respectively
(2). This is consistent with studies in TLR-deficient mice
showing important roles for TLR7 and TLR9 in response to
flu and HSV, respectively (5, 24). In addition, we could not
detect any biological response to either virus using DCs from
MyD88-deficient mice (unpublished data). These results also
demonstrate the ability of IRS 954 to inhibit IFN-
 
 
 
 produc-
tion by viruses, an important finding given the association of
virus infections and exacerbations of lupus (18).
 
IRS inhibit IFN-
 
 
 
 from human PDCs after stimulation with 
either anti-dsDNA or anti-RNP ICs
 
Host-derived nucleic acids, in the form of ICs, potentially
represent a second type of TLR-mediated signal for the pro-
Figure 4. IRS retain similar specificity in human cells. Purified human 
B cells were stimulated with 0.7  M 1018 ISS (left) or 1  M R848 (right) 
alone or in the presence of IRS 869, IRS 661, or IRS 954 at 0.7  M and 2.8  M, 
respectively. IL-6 production was measured by ELISA and plotted as a 
percentage of 1018 ISS or R848 alone. Means of maximum levels of IL-6 
were 2,904 pg/ml (R848) and 851 pg/ml (1018 ISS). Values represent means   
SEM of 10 (1018 ISS) and 6 (R848) independent donors. ***, P   0.001.
Figure 3. IRS are active in vivo to block TLR7 stimulation. BALB/c mice 
were injected i.p. with inactive control ODN or various amounts of IRS 954 
as indicated. 2 h later, mice were injected i.p. route R848. 2 h after the R848 
injection, the serum was collected, and IL-12 was measured by immunoassay. 
Values represent means   SEM of a group of 10 mice. ***, P   0.001. 
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duction of IFN-
 
 
 
 by PDCs. ICs isolated from SLE patients
that are composed of either anti-DNA antibodies and DNA
or anti-RNP antibodies and RNP derived from apoptotic
cells have been shown to be potent inducers of IFN-
 
 
 
 by
PBMCs from normal individuals (19). The roles of DNA-
and RNA-specific TLRs in this induction were not evalu-
ated; however, stimulation of proliferation and antibody
production of mouse B cells by DNA-containing ICs have
been shown to involve TLR9 and recognition of CpG mo-
tifs (14). This stimulation by self–nucleic acids could explain
the chronic elevation of IFN-
 
 
 
 and IFN-
 
 
 
–induced genes
and the enhanced activation of PDCs frequently associated
with lupus. Isolated PDCs from healthy donors were cul-
tured in the presence of ICs (either anti-dsDNA or RNA-
containing anti-RNP antibodies) and UV-treated apoptotic
U937 cells as a source of nucleic acids and associated pro-
teins. Sera from anti-dsDNA–positive SLE patients (Fig. 7
A) and purified IgG from anti-RNP–positive SLE patients
(Fig. 7 C) induced substantial levels of IFN-
 
  from PDCs,
which demonstrates that IFN-  production induced by ICs
in PBMCs originates from the PDCs. As previously de-
scribed, in contrast to anti-DNA–positive serum, ICs from
anti-RNP–positive patients need to be purified in order to
effectively stimulate IFN-  (19). Strikingly, when added to
the cultures, the TLR7 inhibitor IRS 661 efficiently blocked
anti-RNP– but not anti-DNA–induced IFN- , whereas
IRS 954, which inhibits TLR7 and TLR9, blocked stimula-
tion by both types of ICs (Fig. 7, B and D). The addition of
nucleases has been shown to dramatically reduce the IFN- 
response to ICs (25). This demonstrates that nucleic acids
from mammalian origin together with autoantibodies can
activate TLRs and induce the production of IFN-  by
PDCs. DNA–anti-dsDNA ICs induced IFN-  through
TLR9 because IRS 954 but not IRS 661 could block the re-
sponse (Fig. 7 B), whereas RNA protein particles–anti-RNP
ICs induced IFN-  through the stimulation of TLR7, as
both IRS 661 and IRS 954 could inhibit the IFN-  re-
sponse (Fig, 7 D).
DISCUSSION
TLRs are among the most widely expressed recognition re-
ceptors of the innate immune system and recognize a very di-
verse set of molecules derived from pathogenic microorgan-
isms known as pathogen-associated molecule patterns. 10
different TLRs have been identified in humans that recognize
conserved microbial components, initiate specific biological
responses, and are thus essential components of the innate re-
Figure 5. IRS specific for TLR7 act independently of TLR9. Spleno-
cytes from C57BL/6 (closed bars) and TLR9-deficient (hatched bars) mice 
were stimulated for 48 h with R848 (A) or 1018 ISS (B) alone or in the 
presence of IRS 661 or IRS 954 at different concentrations. IL-6 production 
was measured by ELISA. Values represent means   SEM of three independent 
experiments. **, P   0.01; ***, P   0.001.
Figure 6. IRS inhibit IFN-  from human PDCs after stimulation with 
DNA or RNA viruses. Purified human PDCs were stimulated with (A and B) 
UV-irradiated HSV (MOI   5) or (C and D) heat-inactivated influenza virus 
(MOI   2) alone or in the presence of different concentrations of IRS 954, 
IRS 661, or a control sequence. After 48 h of culture, supernatants were 
harvested and IFN-  was measured by ELISA and plotted as a percentage 
of virus stimulation alone. Means of maximum levels of IFN-  were 
34,308 pg/ml (HSV) and 40,599 pg/ml (Influenza). Values represent means   
SEM of 13 (A), 12 (B), 8 (C), and 13 (D) donors. *, P   0.1; ***, P   0.001.TLR INHIBITORS TO TREAT LUPUS | Barrat et al. 1136
sponse to infection. Interestingly, 4 of these 10 TLRs have
been implicated in the binding of nucleic acids. TLR3 recog-
nizes dsRNA from viruses and can also be stimulated by Poly
I:C; TLR7/8 recognize ssRNA; and TLR9 recognizes bacte-
rial and viral DNA and synthetic oligonucleotides containing
unmethylated CG dinucleotides (1, 2). Activation of TLRs
without appropriate control, however, can lead to substantial
inflammation resulting in tissue damage and autoimmunity
(9, 10). Recently, Wang et al. reported that the production of
proinflammatory cytokines in response to West Nile virus, a
dsRNA virus, was reduced in TLR3-deficient mice. This re-
duction did not affect viral load in the mice but rather pro-
tected them from the TLR3-dependent inflammation that
promoted destruction of the blood–brain barrier (8). Exam-
ples of TLR4 involvement in the induction of colitis or mi-
crobial sepsis are well defined (7). Other examples link TLR
stimulation and atherosclerosis (10). Various mechanisms of
control have been established to avoid unwanted TLR acti-
vation. Their expression is restricted to certain subsets of cells,
and their level of expression is usually down-regulated after
activation through a negative feedback loop. Furthermore,
TLR and regulatory T cells cross-regulate each other in order
to balance TLR-induced inflammation and suppression by
regulatory T cells. As shown by Pasare et al., APCs, when
stimulated through their TLRs, induce signals that will block
the suppressive action of regulatory T cells (40). Conversely,
regulatory T cells can secrete cytokines such as IL-10 that are
known to inhibit TLR stimulation (41, 42).
In addition, there is increasing evidence that TLRs can
also be activated by endogenous ligands (9), and it is essential
that these receptors can discriminate self from nonself to pre-
vent undesirable inflammation. For TLRs recognizing nu-
cleic acids, the distinction between nucleic acids from mam-
malian versus microbial origin might be very difficult. The
major difference between microbial and mammalian DNA is
the level of methylation, whereas there are no clear sequen-
tial or structural differences for RNA. All four receptors that
recognize RNA and DNA products are localized in intracel-
lular compartments that could be one of the mechanisms to
prevent undesirable TLR activation by endogenous RNA
and DNA. Collectively, this suggests that TLR stimulation
can be an important factor in the development of autoim-
Figure 7. IRS inhibit IFN-  from human PDCs after stimulation 
with either anti-dsDNA or anti-RNP ICs. Purified human PDCs were 
cultured for 48 h with UV-irradiated U937 cells and (A) serum (10% final 
concentration) from six different anti-dsDNA–positive SLE patients, (B) serum 
(10% final concentration) from an anti-dsDNA–positive SLE patient (260 IU/ml 
of anti-dsDNA antibodies and negative for anti-RNP autoantibodies), 
(C) purified IgG (0.5 mg/ml final concentration) from three different anti-
RNP–positive SLE patients, or (D) purified IgG (0.5 mg/ml final concentration) 
from an anti-RNP–positive SLE patient (142 U/ml of antiautoantibodies 
and negative for anti-dsDNA antibodies). (B and D) Cells were stimulated 
with ICs alone or in the presence of control ODN, IRS 661, or IRS 954. Patient 
D (B) and patient A (D) were used as sources of ICs. IFN-  was measured 
by ELISA. Values represent means   SEM of eight (B) and six (D) PDC 
donors. *, P   0.1; **, P   0.01; ***, P   0.001.JEM VOL. 202, October 17, 2005 1137
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munity, and the ability to control TLR activation may have
great therapeutic potential.
We and others have reported oligonucleotide sequences
that can inhibit TLR9 activation mediated by CpG-contain-
ing oligonucleotides (30–36). These sequences are active on
both mouse and human cells in vitro and in mice in vivo.
We recently extended this to show that IRS could prevent
IFN-  production from PDCs after TLR9 activation (36).
Furthermore, coinjection of IRS with ISS in mice treated
with D-galactosamine prevented death, demonstrating that
IRS are potent enough in vivo to prevent massive systemic
inflammation caused by TLR9 activation (36). Some IRS
have been shown to have efficacy in vivo in severe autoim-
mune models (34, 37, 38, 43). However, the use of com-
plete Freund’s adjuvant in some of these models, which in-
cludes mycobacterial DNA, renders these experiments
difficult to interpret, because the observed effect of IRS may
be by inhibiting the adjuvant and not the resulting pathol-
ogy. Further experiments using complete Freund’s adjuvant–
free models will be necessary to address the potential of IRS
to prevent autoimmunity. We have now developed three se-
ries of IRS, including inhibitors of TLR9, inhibitors of
TLR7 but not TLR9, and, most interestingly, sequences
that inhibit signals through these two receptors. The mecha-
nism of action of IRS is not known; however, evidence to
date and the pattern of specificity of these inhibitors suggest
that the effect is targeted to the receptor either through
competitive antagonism or another mechanism. We have yet
to find any activity of IRS when used alone, and broader as-
says such as microarray analysis may be necessary to conclude
whether IRS have direct activities.
SLE affects  1,000,000 people in the United States
alone, primarily young and middle-aged women. The etiol-
ogy of the disease is unknown, but a strong genetic compo-
nent appears to be involved. SLE is a relapsing, remitting dis-
ease with devastating consequences and is poorly treated or
prevented with existing therapies. Patients suffer from kidney
dysfunction leading to renal failure and a wide and variable
range of symptoms, including arthritis, fever, skin rashes, and
brain inflammation. ICs of autoantibodies to chromatin and
RNA protein particles (snRNP) are diagnostic for SLE
and are thought to play an important role in the pathogenesis
of the disease. Increased serum levels of IFN-  have been ob-
served in many SLE patients and correlate with both disease
activity and key disease markers, such as anti-DNA antibodies
(15–17, 19). Furthermore, a set of characteristic IFN- –
inducible genes are constitutively up-regulated in blood cells
of SLE patients (20, 44–46). These elevated IFN-  levels may
have a direct role in the pathology of lupus because patients
with nonautoimmune disorders who are treated with IFN- 
can develop antinuclear antibodies, anti-dsDNA antibodies,
and occasionally SLE as well. Viral infections, UV skin injury,
or other events leading to IFN-  induction are known to be
activators of flares of SLE. In addition, NZB mice, which
spontaneously develop a lupus-like disease, have less severe
disease with delayed onset when made deficient for the IFN- 
receptor (47).
There is considerable evidence that chronically activated
PDCs and the IFN-  that they produce in response to TLR
stimulation are involved in the pathogenesis of SLE. Patients
with SLE have a 50–100-fold decrease in the number of
PDCs circulating in the blood (20, 21). This decrease appears
caused by in vivo activation followed by cell migration into
peripheral lymphoid tissues and sites of inflammation. Indeed,
activated PDCs have been observed to accumulate in cutane-
ous lupus erythematosus lesions (22, 23). These cells, when
activated with viruses, can produce large amounts of IFN- .
In addition, it was recently shown that ICs present in serum
samples from SLE patients can cause the production of IFN- 
by PBMCs in vitro. A growing body of evidence supports
the idea that TLR activation plays a central role in the main-
tenance and progression of the disease by promoting elevated
IFN-  levels. TLR7 and TLR9 are particularly relevant to
SLE, as they are expressed by human PDCs, and stimulation
through these receptors leads to very high levels of IFN- 
production by PDCs. Exogenous viruses acting through these
TLRs would be expected to induce IFN-  and thus exacer-
bate the disease, and this is consistent with the observed asso-
ciation of lupus flares with viral infections. We show that ICs
associated with self-DNA and RNA can directly activate
PDCs to make IFN- . The recognition by TLRs is likely fa-
cilitated by the expression of Fc RII on PDCs, allowing effi-
cient uptake of the self–nucleic acid into the TLR-containing
endosomal compartments (29, 48). These ICs are thus en-
dogenous IFN-  inducers, and the resulting IFN-  produc-
tion could perpetuate the autoimmune process. In addition,
the role of ICs in the pathogenesis of lupus is complex, and a
similar mode of activation could occur for B cells, as previ-
ously shown in mice (14).
We show that immunoregulatory sequences such as IRS
954 can inhibit signaling through TLR7 and TLR9 and de-
crease IFN-  produced by PDCs either in response to DNA
and RNA viruses or to both types of circulating ICs isolated
from lupus patients. IRS 954 also inhibits the activation of B
cells through TLR7/8 and TLR9, a process that, in concert
with a signal through the B cell receptor, can lead to pro-
duction of autoantibodies specific for both the nucleic acid
and immunoglobulin components of ICs (14). Our work
demonstrates that mammalian RNA and DNA, when com-
plexed with autoantibodies, can represent potent self-anti-
gens for TLR7 or TLR9, respectively, and that this inappro-
priate self-recognition by the innate immune system may
play a substantial role in autoimmune diseases such as lupus.
Treatment with an IRS has the potential to modulate the
major source of excessive IFN-  in SLE, without com-
pletely preventing the acute IFN-  responses to viral infec-
tion mediated by other recognition mechanisms, such as
TLR3 and protein kinase R. This approach could thus be
less immunosuppressive than therapies aimed at blocking
IFN-  interaction with its receptor; however, this will haveTLR INHIBITORS TO TREAT LUPUS | Barrat et al. 1138
to be evaluated in further studies. Using inhibitors of TLR
represents a new approach to treatment of SLE with the po-
tential to reduce symptoms and prevent relapses through in-
hibition of a key step in disease pathogenesis.
MATERIALS AND METHODS
ODN synthesis. Phosphorothioate ODNs were prepared as previously de-
scribed (42). The prototypes for the IRS classes used were IRS 869 (5 -TCC-
TGGAGGGGTTGT-3 ), IRS 661 (5 -TGCTTGCAAGCTTGCAAGCA-
3 ), and IRS 954, 5 -TGCTCCTGGAGGGGTTGT-3 . Control oligonu-
cleotides were 5 -TCCTGCAGGTTAAGT-3 and 5 -TCCTGGCGGAA-
AAGT-3 . CpG-containing ISS was 1018 (5 -TGACTGTGAACGTTCG-
AGATGA-3 ). All ODNs had  5 endotoxin U/mg ODN, determined by
Limulus amebocyte lysate assay (BioWhittaker).
Purification of ICs of SLE patients. Serum samples from SLE patients
were obtained from Golden West Biologicals, the Binding Site, and Sera-
Care. All samples were filtered through a 0.45- m polyvinylidene fluoride
syringe before purification. Anti-dsDNA and anti-RNP titer levels were
measured using commercially available ELISA kits (Corgenix). Samples
were compared with a positive control provided by the manufacturer. Posi-
tive anti-dsDNA samples had an activity greater than 122 IU/ml. Positive
anti-RNP samples had an activity greater than 22 U/ml. IgG from anti-
RNP–positive patients was purified using HiTrap Protein G HP column
(GE Healthcare). Once purified, IgG were desalted and then quantified.
In vitro stimulation of mouse cell subsets. Spleens from 6- to 12-wk-
old BALB/c mice were harvested, and the splenocytes were prepared using
standard techniques. Cells were stimulated with 0.7  M 1018 ISS, 1  M
R848, 5  g/ml LPS, 0.1  g/ml Pam3Cys, 1  g/ml Flagellin, or 50  g/ml
Poly I:C (Invivogen) in the presence of the amount of IRS indicated in the
figures. Experiments with mice were approved by the Institutional Animal
Care and Use Committee of Northview Pacific Laboratories.
In vivo experiments. 6–12-wk-old BALB/c mice were used for all in
vivo experiments. Mice were first injected i.p. with variable quantities of
IRS as mentioned in the figure legends, followed 2 h later by 2.5  g R848.
All injections used ODN in saline. 2 h after injections, blood was harvested,
and serum was prepared using standard procedures.
Isolation and in vitro stimulation of purified human PDCs. Buffy
coats were obtained from the Stanford Blood Center. All cells were used
under protocols approved by the Institutional Review Board. PDCs were
isolated using BDCA-4 enrichment as previously described (42). Purity was
routinely  97%. PDC experiments were conducted with 3–5   104 PDC/
well cultured in 96-well roundbottom plates. HSV-1 (gift from R. Pyles,
University of Texas Medical Branch, Galveston, TX) was UV inactivated
and used at a multiplicity of infection (MOI) of 5. Influenza virus (H1N1,
strain A/PR/8/34) from American Type Culture Collection was inacti-
vated for 30 min at 56 C and used at an MOI of 2. Alternatively, 30,000
PDCs were cultured with 50,000 UV-irradiated (60 mJ) U937 cells in the
presence of 10% serum from anti-dsDNA–positive SLE patients or 0.5 mg/
ml of purified IgG from anti-RNP–positive SLE patients. Cells were cul-
tured for 48 h and supernatants harvested for ELISA.
Isolation and in vitro stimulation of purified human B cells and
monocytes. B cells and monocytes were isolated using CD19 and CD14
enrichment, respectively, as previously described (36). Purity was routinely
99%. Experiments were conducted with 2–4   105 B cells or 2   105
monocytes per well cultured in 96-well flatbottom plates.
Real-time quantitative PCR (TaqMan) analysis. RNA from purified
human monocytes was isolated and converted to cDNA, and PCR reac-
tions were performed as described previously (42). The human sequences
for synthesized primers and the calculation method were as previously de-
scribed (42). In brief, threshold cycle (CT) values for each gene were nor-
malized to the housekeeping gene HPRT using the formula 1.8  
(HKG GENE)   1,000, where HKG is the mean CT of triplicate HPRT
runs, GENE is the mean CT of duplicate runs of the gene of interest, and
1,000 is arbitrarily chosen as a factor to bring all values above 0.
Online supplemental material. Fig. S1 shows the effect of TLR7 inhibi-
tors on purified human monocytes activated through TLR8. Expression levels
of TLR7, TLR8, and TLR9 were evaluated using quantitative PCR. IL-6 and
TNF-  production were measured by ELISA. Online supplemental material is
available at http://www.jem.org/cgi.content/full/jem.20050914/DC1.
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